SCHEMBL13065792

SCHEMBL13065792

O=C(O)CCc1ccc(OCc2ccc(CN3CCc4ccccc4C3)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 9/20 0.64
L3MBTL1 Q9Y468 1/20 0.63
FFAR4 Q5NUL3 2/20 0.61
REV1 Q9UBZ9 1/20 0.57
HRH3 Q9Y5N1 2/20 0.56
PRMT5 O14744 2/20 0.55
WDR77 Q9BQA1 2/20 0.55
RXRA P19793 1/20 0.55
RXRB P28702 1/20 0.55
RXRG P48443 1/20 0.55
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
NPC1 O15118 1/20 0.54
TNF P01375 1/20 0.54
RAB9A P51151 1/20 0.54
NOD2 Q9HC29 1/20 0.54
NOD1 Q9Y239 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2827591 0.95 FFAR1 (0.59) FFAR1L3MBTL1FFAR4REV1HRH3
SCHEMBL21172122 0.92 FFAR1 (0.68) FFAR1FFAR4HRH3RXRARXRB
SCHEMBL19266404 0.91 FFAR1 (0.61) FFAR1L3MBTL1FFAR4HRH3PRMT5
SCHEMBL21171655 0.88 FFAR1 (0.61) FFAR1L3MBTL1FFAR4REV1HRH3
SCHEMBL28449037 0.85 FFAR1 (0.60) FFAR1L3MBTL1REV1PRMT5WDR77
SCHEMBL2827594 0.84 L3MBTL1 (0.52) FFAR1L3MBTL1REV1HRH3PRMT5
SCHEMBL19266392 0.84 REV1 (0.61) FFAR1L3MBTL1REV1HRH3PRMT5
SCHEMBL21171853 0.82 FFAR1 (0.49) FFAR1L3MBTL1FFAR4HRH3PRMT5
SCHEMBL21171660 0.80 FFAR1 (0.55) FFAR1FFAR4HRH3PRMT5WDR77
SCHEMBL21171687 0.80 RXRA (0.57) FFAR1FFAR4HRH3RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3207928-B1 COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES HYUNDAI PHARM CO LTD (KR) 2021-03-10 EP disclosed
EP-2987791-B1 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, SUITABLE FOR PREVENTING AND TREATING METABOLIC DISEASES HYUNDAI PHARM CO LTD (KR) 2019-07-17 EP disclosed
EP-2253315-A1 Alkoxyphenylpropanoic acid derivatives Takeda Pharmaceutical Company Limited (JP) 2010-11-24 EP disclosed
US-7517910-B2 Alkoxyphenylpropanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-14 US disclosed
US-7517910-B2 Alkoxyphenylpropanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-14 US disclosed
US-20070213364-A1 Alkoxyphenylpropanoic Acid Derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-09-13 US disclosed
US-20070213364-A1 Alkoxyphenylpropanoic Acid Derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213364-A1 Alkoxyphenylpropanoic Acid Derivatives GPR119, FFAR1, GPR55 FFAR1 2/4885L3MBTL1 3748/4885FFAR4 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.